By otakuyassine3@gmail.com 
Shares of uniQure (NASDAQ:QURE – Get Free Report) have been assigned an average rating of “Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $33.88.
QURE has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, December 10th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Stifel Nicolaus boosted their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday. Cantor Fitzgerald upped their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Leerink Partners lifted their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th.
Read Our Latest Research Report on uniQure
Insider Buying and Selling at uniQure
In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.74% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of QURE. RTW Investments LP bought a new stake in uniQure during the third quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the last quarter. Atria Investments Inc bought a new stake in shares of uniQure during the 3rd quarter worth $53,000. Quarry LP purchased a new position in uniQure in the third quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.
uniQure Stock Performance
Shares of QURE opened at $15.47 on Friday. The stock has a 50 day moving average of $7.90 and a 200 day moving average of $6.68. The company has a market capitalization of $754.05 million, a price-to-earnings ratio of -3.12 and a beta of 0.89. uniQure has a 12 month low of $3.73 and a 12 month high of $17.71. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.
uniQure (NASDAQ:QURE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. As a group, sell-side analysts forecast that uniQure will post -3.82 earnings per share for the current year.
uniQure Company Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease.
See Also
Receive News & Ratings for uniQure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for uniQure and related companies with MarketBeat.com’s FREE daily email newsletter.